StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

Research analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their price target on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Evogene Price Performance

Shares of EVGN stock opened at $1.29 on Friday. Evogene has a one year low of $1.20 and a one year high of $10.40. The company’s fifty day moving average price is $1.88 and its 200-day moving average price is $3.68. The company has a market capitalization of $6.92 million, a price-to-earnings ratio of -0.29 and a beta of 1.36.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.